+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID06956482

Evaluating Extended Prednisolone and N-Acetylcysteine Treatments for Severe Alcoholic Hepatitis in Adults Aged 18 to 75

Led by University Hospital, Lille · Updated on 2026-06-01

477

Participants Needed

1

Research Sites

195 weeks

Total Duration

AI-Summary

What This Trial Is About

This trial focuses on patients with severe alcoholic hepatitis, a serious liver condition characterized by significant liver damage due to alcohol use. Researchers are studying new approaches to improve outcomes beyond the current standard treatment, prednisolone, which improves short-term survival but is not ideal for all patients. The study aims to reduce both mortality and liver impairment by evaluating two new strategies in this population. Participants will be randomly assigned to one of three treatment groups. One group receives N-acetylcysteine for five days combined with prednisolone for 30 days, followed by a placebo for another 30 days. The second group receives a placebo instead of N-acetylcysteine along with prednisolone for 30 days, then placebo for 30 days. The third group receives placebo for five days with prednisolone for 30 days followed by a tapering prednisolone dose for an additional 30 days. Treatment and placebo are administered according to these schedules to assess their effects. During the study, participants liver function and survival will be closely monitored, with the main outcome measured at 90 days to assess the rate of patients alive with compensated liver disease. Researchers will also use the Lille score to evaluate treatment response after 7 days. Participants will undergo regular assessments, including clinical evaluations and laboratory tests, throughout the treatment and follow-up periods. The total participation may extend beyond the initial 30-day treatment to include the additional 30-day follow-up phase.

CONDITIONS

Brief Title

PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis

Research Team

A

Alexandre Louvet, Prof.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here